Firstly, overexpression of ribosomal S6 kinases RPS6KA2 (RSK3) and RPS6KA6 (RSK4) promoted breast cancer growth upon PI3K inhibition treatment, which can be reversed by addition of MEK- or RSK-specific inhibitors (Serra et al., 2013). This evidence concerns the gene RPS6KA2 and breast carcinoma.